Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2011

Conditions
Philadelphia Chromosome-positive Chronic Myelocytic Leukemia
Interventions
PROCEDURE

Stem cell transplantation

Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect \> 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.

Trial Locations (1)

31096

Rambam Health Care Campus, Haifa

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Miltenyi Biomedicine GmbH

INDUSTRY

lead

Rambam Health Care Campus

OTHER